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in Patients With Mitral Valve Prolapse
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Recent studies have described the occurrence of complex ventricular arrhythmias
and sudden cardiac death among patients with mitral valve prolapse (MVP). The
reported incidence rate of sudden cardiac death or ventricular tachycardia is about
1–1.5% among patients with MVP. Various imaging markers have been associated
with this increased risk, including mitral annular disjunction, replacement fibrosis by late
gadolinium enhancement, and mechanical dispersion. In this review, we briefly discuss
how multimodality cardiac imaging can be applied to identify MVP patients with high risk
of sudden cardiac death and complex ventricular arrhythmias.
Keywords: mitral valve prolapse, cardiac imaging, ventricular tachycardia, echocardiagraphy, cardiac magnet
resonance imaging
INTRODUCTION
Mitral valve prolapse (MVP) has received renewed attention due to several studies documenting
its association with scar substrate and increased risk of complex ventricular arrhythmias (VA)
and sudden cardiac death (SCD) (1–3). Other important complications related to MVP are mitral
regurgitation, infective endocarditis, cerebral embolic events, and heart failure (4). Historically, a
mid–late systolic click was first described to be associated with mitral regurgitation by Barlow and
Pocock (5). Later, Criley et al. demonstrated that this click associated with mitral regurgitation is
due to mitral valve prolapse (6).
The current echocardiographic definition of MVP is displacement of one or both mitral leaflets
in the left atrium below the annulus by at least 2mm in the parasternal long-axis view (7). The
prevalence of MVP in the general population is currently thought to be around 2–3% (8, 9).
However, historically, the reported prevalence of MVP has been described to be as high as 17–
35% (10, 11). These discrepancies are related to initial reports which defined MVP as the presence
of 2mm leaflet displacement in any apical echocardiographic view (two-, three-, or four-chamber).
This led to an overdiagnosis of MVP primarily due to the assumption that the mitral valve is a
planar structure, which was later refuted by the pioneering work of Levine et al. in the latter half
of the 1980s (7, 12). Most of the MVP cases are sporadic in nature; however, studies have also
demonstrated a genetic association (13, 14).
This review will focus on MVP due to myxomatous valvular degeneration. In myxomatous
valve degeneration, diffuse thickening, redundancy, and elongation of mitral valve leaflets occur
in association with an abnormality of the chordae. Barlow’s disease and fibroelastic deficiency
(FED) are ends of the myxomatous MVP spectrum. Barlow’s disease is often found in middle-
aged patients with severe annular dilatation, excessive valvular tissue, thickened or thin chordae,
and prolapse of most of the mitral leaflet segments (15). On the other hand, FED is more often
Tayal et al. Cardiac Imaging in MVP
found in elderly patients with less severe dilatation of the mitral
annulus and thickening of valve tissue predominantly within
the prolapse segments with thinner non-prolapse segments and
chordae (15).
In addition to diagnosing MVP and quantifying associated
mitral regurgitation, cardiac imaging is emerging as a tool to risk
stratify for malignant VA and SCD. In this review, we briefly
discuss recent studies which have identified cardiac imaging-




There are two broad sets of data on MVP and SCD in the
literature: one is from autopsy studies of subjects with SCD
and the other is from observational studies on the incidence of
SCD among living patients with MVP. The cause of SCD in
MVP patients is assumed to be malignant VA (16, 17). In fact, a
recent study identified a strong association between VA burden
and increasing mortality risk among patients with MVP (18).
Notably, data on the true incidence of MVP in SCD patients from
autopsy studies is underestimated (19). Many studies despite
the confirmed presence of MVP in SCD patients categorized
them as “undetermined” (19). Ameta-analysis found a significant
heterogeneity among autopsy studies investigating the cause of
SCD (3). They reported that MVP was present in 11.7% of SCD
patients without other structural heart disease (3). Basso et al.
reported MVP to be the third most common finding in SCD
autopsy cases of young subjects (<40 years) with a prevalence
of 12% (20). Another study from France reviewed negative
medicolegal autopsies of 1,000 adults (<65 years) for cardiac
causes and found 125 subjects had MVP (21). All these suggest
MVP to be highly prevalent among SCD cases.
Among living patients with MVP, there is wide variability
in the limited data reported on the incidence of SCD in MVP.
A meta-analysis reported the incidence of SCD to be 0.14%
from two observational studies comprising 520 patients (3). Most
likely, this is underreported due to lack of studies where data
have been collected systematically. A recent large prospective
study (N = 177), where MVP was diagnosed by cardiac magnetic
resonance (CMR), reported 1.2% annual event rate of SCD
or malignant VA (2). The reported incidence of premature
ventricular extrasystole (PVC) or ventricular tachycardia is very
high on 24-h ambulatory Holter monitoring among patients with
MVP with a recent study of consecutive patients (n = 595) with
MVP and 24-h ambulatoryHoltermonitoring finding nearly 43%
having either PVC burden >5% or ventricular tachycardia (18).
RISK STRATIFICATION USING CLINICAL
VARIABLES
Demographically, MVP patients who suffer from SCD are
described to be younger and more often females (1, 17, 22).
T-wave inversion/ST-segment depression and QTc prolongation
are often described in living patients with MVP (1, 18, 23, 24).
Furthermore, a recent large series (n = 595) found the presence
of T-wave inversion/ST-segment depression to be associated with
a nearly 2-fold increased risk of mild–moderate VA and 8-fold
increased risk of severe VA (18). Basso et al. found T-wave
inversion in the inferior leads of antemortem electrocardiogram
in 10 out 12 patients with MVP who suffered from SCD (1).
APPLICATION OF CARDIAC IMAGING FOR
RISK ASSESSMENT
The diagnosis of MVP is fundamentally made by cardiac
imaging—primarily echocardiography. In addition to
establishing the diagnosis of MVP, echocardiography can
be used to quantify associated mitral regurgitation and left
ventricular (LV) remodeling. Recently, CMR has gained
traction for the assessment of valvular heart disease. It can
provide more accurate quantification of regurgitation volume
and LV remodeling (25). This is in part due to its ability
to compute LV volumes without the need for geometric
assumptions. Taking this into notice, the recent American
Society of Echocardiography recommends referral for CMR
for quantification of mitral regurgitation in scenarios when
there are discordances in the various echocardiographic
parameters (26). For diagnosing MVP, the same criteria
of 2mm leaflet displacement in a three-chamber long-axis
view can be applied to CMR (27). CMR can also identify
the prolapsed scallops within each leaflet using a stack
of cine images (Figure 1) (27). Further, CMR is ideally
suited for risk stratification of VA in patients with MVP
due to its unique ability to non-invasively identify focal
myocardial fibrosis.
Valve Morphology
The presence of bileaflet prolapse on echocardiography with
redundant valve leaflets is one of the major markers of increased
incidence of VA and SCD among patients with MVP. It is
reported that nearly 70% of cases with MVP and SCD had
bileaflet prolapse, while only 26% had posterior leaflet prolapse
(17). A similarly high prevalence of bileaflet prolapse (70%)
among autopsy cases of MVP was noted (1). Redundancy of
mitral valve leaflets, a typical characteristic of myxomatous mitral
valve prolapse, is also described in autopsy cases of SCD with
MVP. A meta-analysis reported that 72 out of 73 confirmed SCD
cases with MVP had redundant leaflets (17).
Myocardial Fibrosis
Autopsy studies have demonstrated the presence of myocardial
fibrosis among patients with MVP (22, 28). However, due to
small sample size and lack of systematic analysis, knowledge gaps
remain. By contrast, CMR allows non-invasive assessment of
focal replacement fibrosis in the LV by utilizing late gadolinium
enhancement (LGE). Using CMR, several studies have reported
the presence of LVmyocardial fibrosis among patients with MVP
(1, 2, 27, 29). These studies show that fibrosis often occurs in
the posteromedial papillary muscle and adjacent LV wall segment
(e.g., inferior and inferolateral LV walls). Besides being focal,
LGE fibrosis is typically of mid-myocardial or patchy pattern
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FIGURE 1 | Cardiac magnetic resonance approach to assessment of mitral valve morphology and mechanism of mitral regurgitation. A stack of high-resolution
three-chamber cine views perpendicular to the short axis of the valve are acquired to investigate individual mitral valve scallops as demonstrated in the artwork.
in patients with MVP (Figure 2) (2). This focal distribution of
fibrosis is unique to patients with MVP and cannot be ascribed
to LV remodeling due to mitral regurgitation (2). One of the
proposed mechanism of this regional fibrosis is repeated systolic
papillary muscle traction (30, 31). A paradoxical movement of
papillary muscle tip during systole is described; while the LV
annulus moves toward the apex, the papillary muscle tip moves
in the opposite direction toward the LA (31). It is hypothesized
that excessive and repeated papillary muscle traction by the
prolapsing leaflets leads to the development of LV fibrosis (32).
However, it is difficult to rule out whether these patients have a
distinct underlying cardiomyopathy causing regional fibrosis.
Several studies provide antecedent association to the presence
of this regional myocardial fibrosis to complex VA (2, 27, 33)
(Table 1). Han et al. demonstrated that 8/10 MVP patients with
complex VA had myocardial fibrosis in the region of papillary
muscle (27). In another study, Kitkungvan et al. prospectively
followed a large series of MVP patients (n = 177) over a
median period of 3.7 years. In his cohort, eight patients had
either ventricular tachycardia (VT) or aborted SCD (2). Of these,
five patients had mid-wall or patchy myocardial fibrosis (non-
ischemic pattern) in the inferobasal region of the LV.
It is well-documented in the literature that the presence
of scar can lead to the genesis of ventricular arrhythmia.
Some viable tissue embedded in dense scar can form slow
conduction channels which can generate a re-entry circuit
causing arrhythmias (34). However, further evidence is needed
to substantiate that this regional fibrosis reported among
patients with MVP is the precipitating cause of ventricular
arrhythmia. These patients may have some underlying electrical
abnormalities like QTc prolongation which is causing the VA.
Therefore, further evidence is provided by electrophysiological
studies to validate this hypothesis. ECG, the most commonly
available electrophysiological tool, has demonstrated that VA
are of right bundle branch block morphology among patients
with MVP indicating that arrhythmias originate in the LV (1).
Moreover, in a study where ablation was attempted among
MVP patients who survived cardiac arrest or have symptomatic
ventricular extrasystoles, the papillary muscle or subvalvular
mitral apparatus region was the primary focus for ventricular
fibrillation or dominant ventricular extrasystole (35). An earlier
study using vectorcardiography of surface electrocardiogram
reported that the origin of ventricular extrasystole in patients
with MVP is in the posterobasal region of the LV (36). These
concordances of the trigger site for arrhythmias and the presence
of myocardial fibrosis in the same region are unlikely to be mere
coincidence. One hypothesis for the genesis of arrhythmias in
these patients is that morphological changes around the mitral
annular plane and papillary muscle, combined with excessive
motion due to mitral prolapse in this region, cause electrical
instability leading to VA (37, 38).
More corroborating evidence is provided by autopsy studies.
Basso et al. systematically investigated all young adults (<40
years) with SCD (n = 650) in the Veneto region in Italy between
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FIGURE 2 | This artwork by Kitkungvan et al. (2) shows the type and regional
distribution of scar among patients with mitral valve prolapse (adapted with
permission from Elsevier and Copyright Clearance Center).
1982 and 2013 (1). They identified 43 patients with MVP. All
43 of these patients had patchy fibrosis in the region of the
posterior papillary muscle and the LV wall adjacent to it. They
further investigated 30 living patients with MVP with evidence
of complex VA and found 28 (93%) of these patients had
myocardial fibrosis in the region of papillary muscle with or
without involvement of the inferobasal region of the LV wall.
Considering these findings, the prior theory of an occult MVP
cardiomyopathy has evolved into that of a localized mechanical
injury of the myocardium such that MVP patients have unique
focal fibrosis which is the substrate of SCD and complex VA (38).
Further evidence against an occult cardiomyopathy was provided
by a recent investigation from our group which noted that
accounting for the volume load from the prolapse volume (e.g.,
the volume of blood above the left ventricular muscle but below
the prolapsing mitral leaflets in the ventricularized portion of the
left atrium) reconciles the disproportionate LV enlargement that
is noted in some MVP patients (39). However, further study is
needed, and this is still an area of active investigation.
Cardiac imaging, specifically CMR, may help in risk
stratification by assessing fibrosis. In fact, a study demonstrated
diffuse LV fibrosis determined by T1 mapping using CMR is also
associated with increased risk of complex VA among patients
with MVP (33). In this study, the authors found a significant
shorter post-contrast T1 time among patients with MVP and
complex VA in comparison with those without VA. However,
further studies are required to understand if this reduced T1 time
is a preceding marker of future LV fibrosis or represents some
underlying cardiomyopathy whichmakes the patients susceptible
to VA.
Mitral Annular Disjunction
Mitral annular disjunction (MAD) is a separation of the posterior
mitral annular hinge point from the LVwall while the attachment
to the atrium and mitral valve is preserved (Figure 3). The
detachment or disjunction allows the excessive motion of the
mitral valve during systole. It was first described by Bharati et al.
in 1981 in a case report. They reported that the annulus was
elongated in patients with MVP and the valve was anchored to
the atrial side creating a separation between the atrium and LV
(40). Subsequently, Hutchinson et al. performed an autopsy study
of the hearts of patients with SCD (n= 900) (41). They described
that 23 (92%) out of 25 hearts with MVP and SCD had MAD,
whereas only 6% of the hearts with other causes of SCD had this
displacement. However, a contradictory report challenging this
concept of MAD in patients with MVP was published soon after
(42). Angelini et al. studied 13 hearts obtained from necropsy
(seven normal and six with MVP). They concluded that there is
variation in the atrioventricular junction in all the hearts. They
proposed that the appearance of separation is in fact produced by
thickening of the valve leaflet at the hinge point and not actual
displacement (42).
Recent studies have reported MAD among patients with
MVP using echocardiography (two-dimensional and three-
dimensional) and CMR (43–47) (Table 1). A systematic review
of these studies showed that nearly 40–60% of patients with
MVP have MAD (48). Studies have described a mean MAD
varying from 5 to 10mm in the long-axis view (parasternal
or apical) using different imaging modalities (43–45, 47). In
fact, a recent study postulated MAD as an independent entity
which results in increased risk of VA (46). In this study, of
116 patients, 115 had MAD by echocardiography and 1 by lone
CMR. The authors reported that nearly 1 out of 4 patients with
MAD did not have concomitant MVP, suggesting that MAD is
not necessarily exclusive to patients with MVP. MAD can be
observed at different locations on the mitral annulus. However,
they observed that MAD is associated with increased risk of VA
when it is present at the posterior wall (46). More recently, a new
approach to measure MAD using cardiac computed tomography
(CCT) is described. In this study, the authors retrospectively
studied patients with MVP (n = 90) for the presence of MAD
(49). They noted MAD detectable by CCT in ∼20% of the
patients with severe mitral regurgitation scheduled for mitral
valve surgery. This proof-of-concept study highlights a potential
role of CCT due to its high spatial resolution, albeit modest
temporal resolution.
Further study and understanding of the concept of MAD are
warranted. There is a need to further characterize changes in
MAD between systole and diastole. Mechanistic data is required
as to whyMADmay cause an increased risk of VT. Moreover, the
impact of surgical mitral valve repair on MAD is unknown and
warrants further investigation.
Mechanical Dispersion and Longitudinal
Strain
Mechanical dyssynchrony is associated with VA in patients
with cardiomyopathies (50, 51). In an experimental model,
it is elucidated that mechanical dyssynchrony is associated
with the expression of certain proteins which makes the heart
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TABLE 1 | Studies describing imaging risk factors in patients with MVP.




Han et al. (27) Retrospective 16 CMR 8 patients (NSVT or couplets) 10 had PM fibrosis. All 8 with VA had
fibrosis
Basso et al. (1) Prospective 44 CMR 30 patients (VF = 2, VT = 1, NSVT =
27)
30 patients with LGE at least one
region (25 PM, 16 inferolateral
mid-wall, 24 inferolateral basal wall).
28 out 30 with VA had fibrosis
Bui et al. (33) Retrospective 41 CMR 14 patients had NSVT (out of 32 with
Holter data)
11 patients had PM fibrosis; 5 out of
14 patients with VA had PM fibrosis
Kitkungvan et al. (2) Prospective 177 CMR 8 patients had inducible VT, sustained
VT, or sudden cardiac death over 3.7
years follow-up.
65 patients had myocardial fibrosis.
The most common locations were
basal or mid inferolateral wall and
basal inferior wall. Arrhythmic event
rate of 7.7% in MVP patients with
replacement fibrosis vs. 2.7% in MVP
patients without replacement fibrosis
Mitral annular disjunction (MAD)
Eriksson et al. (43) Not specified 32 TEE No VA data 31 of 32 patients had MAD with mean
MAD of 10 ± 3 mm
Carmo et al. (47) Retrospective 38 TTE NSVT by Holter (number not
specified)
21 patients had MAD. Average MAD
was 7.4 ± 8.7mm. Patients with
NSVT had larger mean MAD. MAD
≥8.5mm was associated with NSVT
Lee et al. (45) Prospective 101 TEE No VA data 42 patients had MAD with a median
MAD of 8.9 mm
Dejgaard et al. (46) Cross-sectional 116 patients with






26 had NSVT and 14 had sustained
VT or SCD
64 patients with MVP had MAD
Essayagh et al. (44) Prospective 89 CMR NSVT, number not specified 31 patients had MAD with a mean
MAD of 8 ± 4mm. Patients with MAD
had more often NSVT
Mechanical dispersion
Ermakov et al. (54) Retrospective 59 TTE 32 patients had complex VA; among
these, 9 had secondary prevention
ICD
Patients with MVP and VA had higher
mechanical dispersion in comparison
to those with MVP and no VA (mean
59 ± 21 vs. 43 ± 12, P < 0.001)
Pickelhaube sign
Muthukumar et al. (58) Retrospective 21 TTE 10 patients had either VT or VF 12 (57%) patients had Pickelhaube
sign with late high-velocity systolic
spike (≥16 cm/s) with higher
incidence of malignant VA (67 vs.
22%)
CMR, cardiovascular magnetic resonance imaging; VT, ventricular tachycardia; NSVT, non-sustained ventricular tachycardia; VF, ventricular fibrillation; PM, papillary muscle; LGE, late
gadolinium enhancement; VA, ventricular arrhythmia; TTE, transthoracic echocardiography, TEE, transesophageal echocardiography; MVP, mitral valve prolapse.
susceptible to complex VA (52). Mechanical dyssynchrony can
be quantified with multiple techniques, including deformation
imaging and tissue Doppler imaging (53). Mechanical dispersion
is one of the methods to quantify mechanical dyssynchrony.
It is derived using the standard deviation of time-to-peak of
shortening of 18 LV segments using deformation imaging in
the 3 apical views. A recent study investigated the presence
of mechanical dyssynchrony among patients with MVP and
found that patients with MVP and VA had significantly higher
mechanical dispersion compared with those with MVP and no
VA (54). This increased dispersion can be related to myocardial
fibrosis observed in MVP patients. Regional fibrosis causes
delayed contraction in segments with fibrosis leading to increased
mechanical dispersion. This could be another less costly but
effective approach to identify MVP patients at high risk of SCD
and VA using echocardiography.
Besides mechanical dispersion, the magnitude of longitudinal
strain can be used to identify early signs of subclinical
cardiomyopathy among patients with MVP. One study described
decreased longitudinal LV strain in patients with classical MVP
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FIGURE 3 | The mitral annular disjunction (MAD) at the inferolateral wall
denoted by the arrow is demonstrated. It should be noted that MAD increases
from end-diastole to end-systole.
(>5mm leaflet thickness) (55). Another study demonstrated
that basal LV segments have higher longitudinal strain in
patients with Barlow’s disease indicating hypermobility, but
overall, this study did not find any difference in global LV
function between patients with Barlow’s disease and FED
(56). More recently, a study showed that regional post-
systolic shortening is observed more often among MVP
patients with malignant VA (57). However, this study comprises
only 44 patients with just five of them having malignant
VA. Therefore, the findings need to be corroborated in
larger settings.
Pickelhaube Sign
Muthukumar et al. using pulsed-wave Doppler measured mitral
annular velocity in a series of 21 patients with MVP (58).
They noted a distinctive spike mid-systole to late-systole at
the lateral mitral annulus (>16 cm/s) in 12 of 21 patients
(Figure 4) (58). Of these 12 patients, eight patients suffered
from malignant VA at follow-up. No similar spike of increased
velocity was observed at the medial mitral annulus. The authors
hypothesized that the tugging of the posteromedial papillary
muscle of the prolapsing myxomatous mitral leaflet causes
the basal LV wall to pull toward the apex with increased
velocity. Pickelhaube is the term used to describe the German
military helmet which has a spike on top; therefore, this
was used to describe the distinctive spike. Later, the same
group showed that the Pickelhaube sign in patients with
MVP is found with higher frequency at the posterolateral
annulus in the apical long-axis view (59). This is a novel and
relatively simple approach. Larger studies are required to validate
the findings.
RISK STRATIFICATION
MVP is widely prevalent in the community. Although the
risk of SCD may be low, it is of serious concern due to
its devastating consequences. A risk stratification strategy is
needed to identify patients at high risk of this consequential
complication. Figure 5 summarizes the factors associated with
SCD along with the likely mechanism. Among the clinical
variables which suggest increased risk are as follows: female sex,
FIGURE 4 | An echocardiographic example of the “Pickelhaube sign” which
reflects increased velocity at the lateral mitral annulus in mid-systole to
late-systole. The velocity spike is denoted by a white arrow.
bileaflet prolapse, and ECG changes (ST and T-wave changes
in the inferior leads) (17, 38). Besides these, other risk factors
can be clinical history of palpitations or unexplained syncope.
A 24-h Holter monitoring may be considered to estimate
the burden of VA. If any of this is present, a CMR can
be performed for the assessment of LV fibrosis, especially in
the posterior subpapillary region. As explained before, most
likely, this LV fibrosis serves as the substrate for the VA. Slow
conduction channels embedded in this fibrotic region along with
hypermobility of the basal segments and a PVC are possible
triggers leading to a full-fledged malignant VA. The presence of
a concomitant underlying cardiomyopathy and MAD are other
hypothetical factors which may lead to increased risk of SCD
and VA.
FUTURE DIRECTIONS
There are many small series demonstrating SCD and malignant
VA among patients with MVP (1, 2). However, there is
a need for a large multicenter study where patients are
enrolled prospectively and systematically followed at regular
intervals with Holter monitoring and periodic follow-up
with multimodality imaging—particularly echocardiography and
CMR. This will provide insights into the true risk of SCD
and malignant VA among patients with MVP. Imaging may
aid by providing high-risk markers which may identify patients
who warrant closer follow-up. Moreover, imaging findings
along with clinical and genetics/molecular research can be
combined to develop a scoring system which can eventually
be applied to identify patients at high risk of SCD and
considered for implantable cardioverter defibrillator device as
primary prevention. The most recent ACC/AHA/HRS guidelines
from 2017 note the increased risk of VA among patients with
MVP and a potential association with SCD, but there are no
specific recommendations made for therapeutic intervention
(60). Among the imaging risk markers, factors which should
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FIGURE 5 | The clinical risk factors, mechanism, and hypothetical factors still under investigation related to the potential increased risk of malignant ventricular
arrhythmias and sudden cardiac death among patients with MVP are illustrated.
be investigated are the role of LV fibrosis in the posterior
subpapillary region, MAD, T1 mapping, longitudinal strain, and
Pickelhaube signs. The role of other imaging modalities, such as
positron emission tomography (PET) should also be considered.
A recent study using PET demonstrated an increase uptake of
FDGwith concurrent LGE by CMR in patients withMVP, raising
the possibility of an inflammatory or ischemic component in
these segments among asymptomatic patients with MVP (61).
Further studies will provide more insight into the role of PET in
risk stratification of MVP patients.
CONCLUSIONS
MVP is a widely prevalent disease and studies have shown the
increased risk of SCD and complex VA in these patients. Several
imaging markers are shown to be related to this arrhythmic
risk. Aside from its role as a cornerstone for identifying
MVP, echocardiography can serve as a gatekeeper for further
investigations if bileaflet prolapse or signs of any cardiomyopathy
are noted. The strength of CMR is its ability to perform tissue
characterization to identify focal myocardial fibrosis in the
posterior papillary muscle and adjacent LV wall. The presence
of fibrosis has one of the most compelling mechanistic basis and
supporting evidence in the literature. Patients presenting with
syncope, pre-syncope, palpitations, or evidence of VA should be
investigated with CMR for further risk stratification.
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